<DOC>
	<DOCNO>NCT01296971</DOCNO>
	<brief_summary>This open-label , non-comparative study ass safety tolerability individualize combination therapy Copegus ( ribavirin ) Pegasys ( peginterferon alfa-2a ) patient chronic hepatitis C. Patients hepatitis C virus ( HCV ) genotype 1 ( Group A ) receive Copegus 1'000 mg 1'200 mg daily orally 24-72 week . For patient genotype 2 3 HCV ( Group B ) Copegus dose 800 mg daily 16-48 week . Patients previously receive standard pegylated interferon non-responders relapse ( Group C ) receive Copegus 1'000 mg 1'200 mg daily 72 week . Concomitant therapy Pegasys 180 mcg subcutaneously weekly give patient . Anticipated time study treatment 72 week 24-week follow-up .</brief_summary>
	<brief_title>A Study Safety Individualized Combination Therapy With Copegus ( Ribavirin ) Pegasys ( Peginterferon Alfa-2a ) Patients With Chronic Hepatitis C ( MASTER )</brief_title>
	<detailed_description />
	<mesh_term>Hepatitis</mesh_term>
	<mesh_term>Hepatitis A</mesh_term>
	<mesh_term>Hepatitis C</mesh_term>
	<mesh_term>Hepatitis , Chronic</mesh_term>
	<mesh_term>Hepatitis C , Chronic</mesh_term>
	<mesh_term>Ribavirin</mesh_term>
	<mesh_term>Peginterferon alfa-2a</mesh_term>
	<mesh_term>Interferon-alpha</mesh_term>
	<criteria>Adult patient , &gt; /= 18 year age Chronic hepatitis C Measurable serum HVC RNA level Compensated liver disease ( ChildPugh class A ) Treatmentnaive standard pegylated interferon , nonresponder relapse Concomitant hepatitis A B History chronic liver disease cause hepatitis C virus Hepatocellular carcinoma History sign esophageal varix haemorrhage condition indicative decompensated liver disease Treatment systemic antitumor immunomodulatory agent ( include steroid dos exceed physiological one , radiotherapy ) within 6 month prior first dose study drug Pregnant lactate woman , men whose partner pregnant</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2016</verification_date>
</DOC>